Ion Beam Applications SA (EBR:IBAB)
Belgium · Delayed Price · Currency is EUR | Market Cap | 390.28M +36.2% |
| Revenue (ttm) | 620.20M +24.5% |
| Net Income | 12.70M +37.3% |
| EPS | 0.43 +37.0% |
| Shares Out | 29.17M |
| PE Ratio | 31.12 |
| Forward PE | 10.83 |
| Dividend | 0.25 (1.87%) |
| Ex-Dividend Date | Jun 18, 2025 |
| Volume | 19,500 |
| Average Volume | 37,031 |
| Open | 13.30 |
| Previous Close | 13.44 |
| Day's Range | 13.28 - 13.48 |
| 52-Week Range | 9.90 - 15.90 |
| Beta | 1.19 |
| RSI | 42.64 |
| Earnings Date | Apr 30, 2026 |
About Ion Beam Applications
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments in Belgium, the United States, and internationally. It operates through Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production o... [Read more]
Financial Performance
In 2025, Ion Beam Applications's revenue was 620.20 million, an increase of 24.50% compared to the previous year's 498.16 million. Earnings were 12.70 million, an increase of 37.25%.
Financial StatementsNews
Ion Beam Applications Earnings Call Transcript: Q4 2025
Record 2025 revenue and order intake drove profitability improvements, especially in proton therapy, with strong backlog and strategic investments supporting a positive outlook. Guidance for 2026 targets further EBIT growth and margin expansion, with gross margin and cash flow expected to improve as legacy contracts roll off.
Ion Beam Applications Earnings Call Transcript: Q3 2025
Order intake and backlog remain strong, supporting confidence in meeting EBIT guidance of at least $25 million. New financing enhances balance sheet flexibility, while segment performance is robust despite some headwinds in Dosimetry.
Ion Beam Applications Earnings Call Transcript: Q2 2025
Revenue surged 40% year-over-year to EUR 304.9 million, driven by strong backlog conversion and growth across all business units, though gross margin declined due to legacy projects. Guidance for 2025 is reaffirmed, with a minimum EUR 25 million rebit and positive outlook for proton therapy profitability.
Ion Beam Applications Transcript: CMD 2025
Revised summary: Strong competitive positioning, innovation, and a capital-light strategy drive growth in industrial, clinical, and new venture segments. Financial guidance targets 5%-7% annual revenue growth and a 10% EBIT margin by 2028, with profitability from service scale, AI, and efficiency. Proton therapy adoption will accelerate with clinical evidence and global expansion.
Ion Beam Applications Earnings Call Transcript: H2 2024
Record 2024 revenue and profitability driven by strong backlog and segment growth, with a positive outlook for 2025 and beyond. Strategic investments in R&D and new ventures support sustainable margins, while prudent guidance reflects market uncertainties.
Ion Beam Applications Earnings Call Transcript: H1 2024
Revenue grew 22% to €206.5M, with improved margins and a reduced net loss of €10.3M. Backlog conversion accelerated, especially in proton therapy and other accelerators, while the outlook remains strong with midterm EBIT margin targets reiterated.
Ion Beam Applications Earnings Call Transcript: H2 2023
IBA Business Update – Third Quarter 2023
Louvain-La-Neuve, Belgium, 16 November 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter...
Ion Beam Applications Earnings Call Transcript: H1 2023
Ion Beam Applications Earnings Call Transcript: H2 2022
Ion Beam Applications Earnings Call Transcript: H1 2022
IBA Reports Half Year 2022 Results
RECORD ORDER INTAKE AND BACKLOG ACROSS THE GROUP